ARTES and BioSun announce co-development for HPV vaccine

Lan­gen­feld, Ger­many / Tehran, Iran 

ARTES Biotech­nol­o­gy and Bio­Sun Pharmed announced to join forces for the devel­op­ment and man­u­fac­tur­ing of a HPV (human papil­lo­ma virus) vac­cine in Iran.

The agreed long-term col­lab­o­ra­tion involved the strength of both part­ners. ARTES Biotech­nol­o­gy GmbH (ARTES) is spe­cial­ized in cell line and process devel­op­ment of virus like par­ti­cle (VLP) based vac­cines and in tech­nol­o­gy trans­fer for phar­ma­ceu­ti­cal­ly rel­e­vant pro­duc­tion processes. 

Bio­Sun Pharmed Co is involved in the man­u­fac­tur­ing of high qual­i­ty and safe vac­cines and bio­phar­ma­ceu­ti­cal prod­ucts for the domes­tic and inter­na­tion­al markets. 

Human papil­lo­ma virus infec­tion (HPV) is the most com­mon sex­u­al­ly trans­mit­ted infec­tion glob­al­ly. Most peo­ple are infect­ed at some point in their lives. There are approx­i­mate­ly 79 mil­lion men/women active­ly infect­ed with the virus at any point in time. Annu­al­ly, there are 14 mil­lion new­ly diag­nosed cas­es of HPV. HPV infec­tion can cause in warts or pre­can­cer­ous lesions. The pre­can­cer­ous lesions increase the risk of cancer.

In 2012, about 270,000 women died from cer­vi­cal can­cer, more than 85% of these deaths occur­ring in low and mid­dle income countries.

We are extreme­ly delight­ed about the mutu­al­ly agreed col­lab­o­ra­tion. This agree­ment is the next step in ARTES’ strat­e­gy to devel­op from a ser­vice provider for process devel­op­ment to a part­ner for full phar­ma­ceu­ti­cal prod­uct devel­op­ment,” Dr. Michael Pio­ntek, founder and man­ag­ing direc­tor of ARTES Biotechnology.

For the first time, ARTES will be respon­si­ble for process devel­op­ment of API, for­mu­la­tion, qual­i­ty con­trol and sup­ply of pre­clin­i­cal test mate­r­i­al. In addi­tion, ARTES will be engaged in design of the man­u­fac­tur­ing site at Bio­Sun and in selec­tion of third par­ties for GMP manufacturing.

I am real­ly pleased that after tech­ni­cal and com­mer­cial dis­cus­sions, we could final­ly make col­lab­o­ra­tion agree­ment with a well-known and reli­able part­ner for not only pro­duc­ing pre-mas­ter cell banks but also for co-devel­op­ments of our mutu­al inter­est­ed prod­ucts. Our mis­sion is pro­duc­ing high qual­i­ty and afford­able vac­cines and biotech prod­ucts improv­ing health lev­el of com­mu­ni­ty.” Dr. Moham­mad Tagha­vian, man­ag­ing direc­tor of Bio­sun Pharmed.

Finan­cial details of this agree­ment were not disclosed.